Altimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2830 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution - Jun 26th, 2025 6:37 am
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH - Jun 26th, 2025 5:00 am
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 - Jun 25th, 2025 5:12 pm
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions - Jun 13th, 2025 5:30 am
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - May 19th, 2025 5:30 am
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension - May 14th, 2025 7:18 am
Altimmune to Participate at Two Upcoming Investor Conferences - May 14th, 2025 5:30 am
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - May 13th, 2025 5:00 am
Altimmune Announces First Quarter 2025 Financial Results and Business Update - May 13th, 2025 5:00 am
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - May 8th, 2025 5:30 am
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - May 6th, 2025 5:30 am
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - May 1st, 2025 5:30 am
Altimmune to Participate in the Citizens Life Sciences Conference - Apr 30th, 2025 5:30 am
Altimmune's US$42m Market Cap Fall Books Insider Losses - Apr 10th, 2025 5:44 am
Altimmune to Host Virtual R&D Day on March 13, 2025 - Mar 6th, 2025 5:30 am
Altimmune to Participate in the Leerink Global Healthcare Conference - Mar 3rd, 2025 5:30 am
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Feb 28th, 2025 3:29 am
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Feb 27th, 2025 5:00 am
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors - Feb 25th, 2025 5:30 am
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Feb 20th, 2025 5:30 am